Neumora Therapeutics is trading at $0.69, down 5.18% on September 21, 2026, extending a sharp multi-session decline with no clear catalyst identified.
- Searches found no new company-specific announcement explaining the move.
- The latest identified pipeline news is favorable NMRA-215 toxicology results and a planned fourth-quarter 2026 IND submission; both are historical and do not directly explain today’s decline.
- Broad markets are rising, so the drop is not clearly aligned with the session’s risk-on move.